Life Sciences Partners (LSP) has closed its new life sciences fund, ‘LSP5’. The fund surpassed its €152M target and reached the ‘hard cap’ of €250M, making it one of the largest life sciences funds in the EU.
LSP is one of the oldest and most successful Biotech investors in Europe. It claims over 25% return on investment per year in private investment, which is very high.
And it has over $1.2Bn of investment capital raised to date, managed from offices in Amsterdam, Munich and Boston. The new fund (LSP5) will invest in around 20 companies across the areas of drug development, medical devices and diagnostics.
And it has already started to invest, taking positions in 9 such companies.